These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 38596687)

  • 1. Targeting PRAME for acute myeloid leukemia therapy.
    Yang J; Chen M; Ye J; Ma H
    Front Immunol; 2024; 15():1378277. PubMed ID: 38596687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.
    Kirkey DC; Loeb AM; Castro S; McKay CN; Perkins L; Pardo L; Leonti AR; Tang TT; Loken MR; Brodersen LE; Loeb KR; Scheinberg DA; Le Q; Meshinchi S
    Blood Adv; 2023 Apr; 7(7):1178-1189. PubMed ID: 35984639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
    Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
    Steger B; Floro L; Amberger DC; Kroell T; Tischer J; Kolb HJ; Schmetzer HM
    J Immunother; 2020; 43(6):204-215. PubMed ID: 32502139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.
    Matsushita M; Yamazaki R; Ikeda H; Kawakami Y
    Leuk Lymphoma; 2003 Mar; 44(3):439-44. PubMed ID: 12688312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of PRAME gene in adult acute leukemia and its significance in prognosis].
    Zhou PY; Li WJ; Wei CX; Zhou Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1177-81. PubMed ID: 18088461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
    Rezvani K; Yong AS; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Li Y; Kurlander R; Barrett AJ
    Blood; 2009 Mar; 113(10):2245-55. PubMed ID: 18988867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quantification of the PRAME transcripts in patients with acute myeloid leukemia].
    Zhu ZH; Qian J; Lin J; Yao DM; Qian Z; Wang YL; Chen Q; Han LX; Xiao G
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Apr; 27(2):149-52. PubMed ID: 20376794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of PRAME gene in acute leukemia and its clinical significance].
    Zhu YL; Liu J; Zhu P; DU JW; Zhang Y; Gu JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1144-9. PubMed ID: 18088454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia.
    Steinbach D; Hermann J; Viehmann S; Zintl F; Gruhn B
    Cancer Genet Cytogenet; 2002 Mar; 133(2):118-23. PubMed ID: 11943337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
    Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
    Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis.
    Abdelmalak CA; Yahya RS; Elghannam DM; El-Khadragy AE; Abd El Messih HM
    Clin Lab; 2014; 60(1):55-61. PubMed ID: 24600975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
    Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
    Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.